http://www.lmtbio.com  

8952 Schlieren, Grabenstrasse 3

 +41 44 733 85 85
 info@lmtbio.com

LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. It was founded as a spin-off of GlycoVaxyn AG, which was acquired by GSK in February 2015 following a two-year collaboration. LimmaTech is developing vaccines exclusively for GSK and actively explores applications of glycoengineering and protein glycosylation technology in other fields.